Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Time Is Of The Essence As Teva Considers European Assets Bids

Executive Summary

Drug makers and private equity firms expected to submit their offers soon for Teva's oncology and pain businesses in Europe as the Israeli company bids to reduce debt by $5bn by the end of 2017.

Advertisement

Related Content

Teva's US IUD Brings In $1.1bn For The Embattled Generics Firm
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid
Intas Builds Europe Scale With £603m Teva Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099325

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel